Compare LUNG & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | MDAI |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 55.9M |
| IPO Year | 2020 | N/A |
| Metric | LUNG | MDAI |
|---|---|---|
| Price | $2.54 | $1.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $6.81 | $3.25 |
| AVG Volume (30 Days) | ★ 1.1M | 363.1K |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $91,664,000.00 | $23,168,000.00 |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.59 | N/A |
| 52 Week Low | $1.31 | $1.04 |
| 52 Week High | $9.37 | $3.25 |
| Indicator | LUNG | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 43.78 |
| Support Level | $1.96 | $1.63 |
| Resistance Level | $1.74 | $1.76 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 91.13 | 52.31 |
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.